When was Arcturus Therapeutics founded?

Arcturus Therapeutics was founded in 2013 and raised its 1st funding round within a year of its incorporation.

Where is Arcturus Therapeutics located?

Arcturus Therapeutics is headquartered in San Diego, United States. It is registered at Little Rock, Arkansas.

Who is the current CEO of Arcturus Therapeutics?

Joe Payne of Arcturus Therapeutics.

How many employees does Arcturus Therapeutics have?

As of Aug 31, 2026, the latest employee count at Arcturus Therapeutics is 152.

Is Arcturus Therapeutics a funded company?

Arcturus Therapeutics is a funded company, having raised a total of $1.3M across 7 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Apr 05, 2013.

When was the latest funding round of Arcturus Therapeutics?

Arcturus Therapeutics' latest funding was a $***** Grant (prize money) round on Sep 26, 2023, with participation from 1 investor.

Where does Arcturus Therapeutics rank among its competitors?

Arcturus Therapeutics ranks 75th amongst 604 active competitors, of which 187 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Strand Therapeutics, which secured $153M in May, 2025.

Who are the top competitors of Arcturus Therapeutics?

Arcturus Therapeutics' top competitors include BridgeBio, Alnylam and PTC Therapeutics. Among them, Strand Therapeutics secured the most recent funding round in May, 2025.

Arcturus Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of RNAi technologies for the treatment of rare orphan diseases. The company uses two proprietary technologies, LUNAR lipid-mediated delivery and STARR mRNA Technology, to develop RNA medicines for rare and infectious diseases. The company's lead candidate is LUNAR OTC to treat ornithine transcarbamylase deficiency.

Website: arcturusrx.com
Social
Email ID: *****@arcturusrx.com
Phone Number: +1 **********
Registered Address: Little Rock, Arkansas

Key Metrics

Founded Year

2013

Location

San Diego, United States

Stage

Public

Total Funding

$1.3M in 7 rounds

Latest Funding Round

Grant (prize money), Sep 26, 2023, $*****

Investors

Cystic Fibrosis Foundation & 2 more

Ranked

75^th among 604 active competitors

Employee Count

152 as on Aug 31, 2026

Similar Companies

BridgeBio & 703 more

Exit Details

Public

View Arcturus Therapeutics' full profile

Arcturus Therapeutics is associated with 5 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
ARCTURUS CIN: 40103349840 , Latvia, Active	Nov 29, 2010	€0 - €1M (As on Dec 31, 2024)	-	-
ARCTURUS THERAPEUTICS LTD. CIN: 1566049 , United States, Active	Jan 27, 2019	$10M - $50M (As on Dec 31, 2018)	-	-
Arcturus Therapeutics Holdings Inc. CIN: 32-0595345 , United States, Active	Jan 27, 2019	-	170 (As on Dec 31, 2022)	-
Arcturus Therapeutics, Inc. CIN: 461981974 , United States, Active	Dec 31, 1999	-	174 (As on Dec 31, 2024)	-
ARCTURUS INC. CIN: 474447158 , United States, Active	Dec 26, 999	-	5 (As on Dec 31, 2023)	-

Arcturus Therapeutics got listed on Jun 03, 2013.

Click here to take a look at Arcturus Therapeutics's IPO in detail

Arcturus Therapeutics has raised a total funding of $1.3M over 7 rounds. Its first funding round was on Apr 05, 2013. Its latest funding round was a Grant (prize money) round on Sep 26, 2023 for $*****. 1 investor participated in its latest round. Arcturus Therapeutics has 3 institutional investors.

Here is the list of recent funding rounds of Arcturus Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 26, 2023	7165950	Grant (prize money)	7726484	4519518	6161362	4680369
Jan 03, 2018	7101855	Post IPO	5293507	9942629	7264088	8810617
May 30, 2017	6582360	Grant (prize money)	1205587	8773026	6847866	Cystic Fibrosis Foundation

Access funding benchmarks and valuations. Sign up today!

View details of Arcturus Therapeutics's funding rounds and investors

The founders of Arcturus Therapeutics is Joe Payne.

Here are the details of Arcturus Therapeutics' key team members:

Joe Payne: President, CEO and Founder of Arcturus Therapeutics.

View details of Arcturus Therapeutics's Founder profiles and Board Members

Arcturus Therapeutics' employee count trend

Arcturus Therapeutics has 152 employees as of Aug 26. Here is Arcturus Therapeutics's employee count trend over the years:

Employee count trend for Arcturus Therapeutics

Uncover Arcturus Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Arcturus Therapeutics include BridgeBio, Alnylam and PTC Therapeutics. Here is the list of Top 10 competitors of Arcturus Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BridgeBio 2015, Palo Alto (United States), Public	Developer of therapeutics for the treatment of genetic diseases	$434M	Viking Global Investors, KKR & 20 others	81/100
2nd	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 13 others	79/100
3rd	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
4th	Alexion 1992, Zurich (Switzerland), Acquired	Developer of therapies for patients with devastating and rare diseases	$133M	Allen & Company, Invesco & 9 others	74/100
5th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, T. Rowe Price & 6 others	73/100
6th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	71/100
7th	Bluebird Bio 1992, Cambridge (United States), Acquired	Developer of gene therapies for severe genetic and rare diseases	$136M	TVM Capital, Forbion & 10 others	71/100
8th	Agios Pharmaceuticals 2008, Cambridge (United States), Public	Developer of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism	$120M	Arch Venture Partners, Flagship Pioneering ... & 6 others	70/100
9th	Rhythm Pharmaceuticals 2010, Boston (United States), Public	Developer of peptide therapeutics for the treatment of rare genetic deficiencies	$84M	Pfizer Venture Investments, Third Rock Ventures ... & 9 others	70/100
10th	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, Playground Global & 19 others	69/100
75th	Arcturus Therapeutics 2013, San Diego (United States), Public	Developer of RNAi technologies for the treatment of rare orphan diseases	$1.3M	Cystic Fibrosis Foundation, JLABS & 1 others	56/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Arcturus Therapeutics's competitors? Click here to see the top ones

Arcturus Therapeutics has made no investments or acquisitions yet.

Here is the latest report on Arcturus Therapeutics's sector:

Free

Nanotechnology - Sector Report

Edition: August, 2026 (71 Pages)

View all reports related to Arcturus Therapeutics

Media has covered Arcturus Therapeutics for a total of 13 events in the last 1 year, 6 of them have been about company updates and 1 about partnerships.